This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy.
Patients who are planned for cystectomy due to bladder cancer will be considered for enrollment based on inclusion and exclusion criteria.
Properly counselled patients with high grade T1 disease who elect for cystectomy
Properly counselled patients with non-muscle invasive high grade Ta urothelial carcinoma or carcinoma in situ who are unresponsive to intravesical therapy and have elected cystectomy
cT2-T3 muscle invasive urothelial carcinoma for planned cystectomy
Patient who have received prior intravesical therapy or multiple TURBTs can be enrolled (data regarding number of previous TURBTs and type of intravesical therapy will be collected).
Patients who undergo cystectomy with non-curative intent will be excluded.
Patients who have undergone previous definitive pelvic radiation for the purpose of treating bladder malignancy.
Patients who are pregnant or nursing.
Fox Chase Cancer Center
Lead sponsor
Janssen Pharmaceuticals
Collaborator